|1.||Chaudhry, Hina W: 5 articles (02/2014 - 08/2004)|
|2.||Lemmers, Bénédicte: 4 articles (08/2015 - 01/2012)|
|3.||Bendris, Nawal: 4 articles (08/2015 - 01/2012)|
|4.||Cheng, Richard K: 4 articles (02/2014 - 07/2006)|
|5.||Qu, Xiaogang: 3 articles (01/2015 - 06/2008)|
|6.||Ren, Jinsong: 3 articles (01/2015 - 06/2008)|
|7.||Blanchard, Jean Marie: 3 articles (12/2014 - 01/2012)|
|8.||Treeck, Oliver: 3 articles (06/2012 - 06/2007)|
|9.||Ortmann, Olaf: 3 articles (06/2012 - 06/2007)|
|10.||Wolgemuth, Debra J: 3 articles (06/2007 - 02/2004)|
|1.||Colorectal Neoplasms (Colorectal Cancer)
10/01/2012 - "Our recent work, which revealed decreased expression of Cyclin A2 upon metastasis of colorectal cancer, suggests a more complicated situation. "
06/15/2007 - "Here, we show that LKB1 catalytically deficient mutants, when introduced into DLD1p21-/-p53-/- colorectal cancer cells, allowed for progression of cells through to S phase of cell cycle and elicited the expression of Rb, cyclin E, and cyclin A2 whereas the introduction of LKB1 lead to G1 cell cycle arrest independent of p21(WAF/CIP1) and/or p53 expression. "
04/01/2007 - "Likewise, a significant reduction in the development and growth of colorectal tumors was found in Villin-Cre Foxm1-/- mice compared with Foxm1 fl/fl mice after AOM/DSS treatment, which was associated with decreased expression of cyclin A2, cyclin B1, survivin, and T-cell factor 4 genes. "
09/01/2011 - "One SNP (reference SNP [rs] 769236, +1 guanine to adenine [G→A]) at the promoter region of cyclin A2 (CCNA2) also was analyzed in 1989 cancers (300 breast cancers, 450 colorectal cancers, 450 gastric cancers, 367 hepatocellular carcinomas, and 422 lung cancers) and in 1096 controls. "
|2.||Ovarian Neoplasms (Ovarian Cancer)
06/01/2007 - "Heterologous expression of ERbeta1, but not of the exon-deleted ERbeta variants resulted in notably slower cell growth of SK-OV-3 ovarian cancer cells, an effect accompanied by more than tenfold increase of cyclin-dependent kinase inhibitor p21(WAF1) transcript levels and a significant reduction of cyclin A2 mRNA levels. "
|3.||Breast Neoplasms (Breast Cancer)
10/01/2014 - "This study investigates the role of cyclin A2 in regulating endogenous PR activity in T47D breast cancer cells by depleting cyclin A2 expression and measuring PR target genes using q-RT-PCR. "
02/20/2010 - "This study investigated correlations of cyclin A2 and HER2 levels with clinical outcomes in 281 patients with invasive breast cancer in order to identify whether cyclin A2 can serve as a prognostic factor in HER2 negative patients. "
01/01/2014 - "Importantly, we demonstrate that GATA3 downregulation is required for progestin-induced upregulation of cyclin A2 and for progestin-induced in vitro and in vivo breast cancer cell growth."
01/01/2014 - "In addition, we demonstrated that decreased GATA3 levels are required for progestin-induced upregulation of cyclin A2, which mediates the G1 to S phase transition of the cell cycle and was reported to be associated with poor prognosis in breast cancer. "
10/01/2014 - "These results demonstrate that cyclin A2 and its associated kinase activity are important for progestin-induced activation of endogenous PR target genes in breast cancer cells. "
|4.||Osteosarcoma (Osteogenic Sarcoma)
09/01/2007 - "To study the inhibitory effect of small interference RNA (siRNA) targeting cyclin A2 gene on the growth of osteosarcoma MG-63 and human normal skin fibroblast HSF cells and to explore whether cyclin A2 siRNAs could become a useful tool in the treatment of osteosarcoma. "
03/06/2007 - "To study the impact of small interference RNA (siRNA) targeting cyclin A2 gene on the growth of MG-63 and HSF cells and to explore whether cyclin A2 siRNAs could become a useful tool in the treatment of osteosarcoma. "
01/01/2010 - "In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). "
|5.||Germ Cell and Embryonal Neoplasms (Germ Cell Tumor)
|1.||Messenger RNA (mRNA)
|3.||Transcription Factor 7-Like 2 Protein
|4.||Cyclin-Dependent Kinase Inhibitor p21
|5.||Estrogen Receptor beta
|7.||Small Interfering RNA (siRNA)
|1.||Drug Therapy (Chemotherapy)